ERBB2 and breast cancer: Similarly, Juan et al. [47], using next-generation sequencing on 445 HER2-low breast cancer samples, showed that although not statistically significant, PIK3CA mutations were more frequent in HR-positive tumors, while PTEN mutations appeared more common in HR-negative tumors.